The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
Open accessAbstract
Like type‐2 diabetes mellitus (T2DM), neurodegenerative disorders and stroke are an ever increasing, health, social and economic burden for developed Westernized countries. Age is an important risk factor in all of these; due to the rapidly increasing rise in the elderly population T2DM and neurodegenerative disorders, both represent a looming threat to healthcare systems. Whereas several efficacious drugs are currently available to ameliorate T2DM, effective treatments to counteract pathogenic processes of neurodegenerative disorders are lacking and represent a major scientific and pharmaceutical challenge. Epidemiological data indicate an association between T2DM and most major neurodegenerative disorders, including Alzheimer's and Parkinson's diseases. Likewise, there is an association between T2DM and stroke incidence. Studies have revealed that common pathophysiological features, including oxidative stress, insulin resistance, abnormal protein processing and cognitive decline, occur across these. Based on the presence of shared mechanisms and signalling pathways in these seemingly distinct diseases, one could hypothesize that an effective treatment for one disorder could prove beneficial in the others. Glucagon‐like peptide‐1 (GLP‐1)‐based anti‐diabetic drugs have drawn particular attention as an effective new strategy to not only regulate blood glucose but also to reduce apoptotic cell death of pancreatic beta cells in T2DM. Evidence supports a neurotrophic and neuroprotective role of GLP‐1 receptor (R) stimulation in an increasing array of cellular and animal neurodegeneration models as well as in neurogenesis. Herein, we review the physiological role of GLP‐1 in the nervous system, focused towards the potential benefit of GLP‐1R stimulation as an immediately translatable treatment strategy for acute and chronic neurological disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Amyloid Precursor Protein Processing and Alzheimer's Disease
O'Brien, R. J., & Wong, P. C. (2011) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-061010-113613 · Cited by 2,061
Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 1×
“In AD, there are two welldefined abnormal proteins widely regarded to be pivotal to the pathology of the disease; amyloid-b (Ab) and hyperphosphorylated microtubule-associated protein (commonly referred to as tau protein), both of which can form insoluble neurotoxic aggregates (Flament et al., 1990; Chartier-Harlin et…”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 2×
“The stark similarity between T2DM and AD has given rise to the hypothesis and new term for describing AD as, namely, ‘type 3 diabetes’ (Steen et al., 2005; de la Monte, 2009; Kroner, 2009; Akter et al., 2011).”
BackgroundApoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 17×
“As stated, GLP-1-based drugs have proved beneficial in T2DM patients.”
BackgroundInfluentialChartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · cited 2×
“…form of the peptide, particularly in the form of oligomeric assemblies or Ab–derived diffusible ligands (ADDLs), has been described to target synapses, induce neuronal dysfunction and impair cognition (Lacor et al., 2007; Shankar et al., 2008; Ashe and Zahs, 2010; Marchetti and Marie, 2011).”
BackgroundA mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease
Murrell, J., Farlow, M., Ghetti, B., & Benson, M. D. (1991) · Science · doi:10.1126/science.1925564 · Cited by 1,127
Molecular biology of amyotrophic lateral sclerosis: insights from genetics
Pasinelli, P., & Brown, R. H. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1971 · Cited by 1,107 · cited 1×
“Whereas most cases of ALS occur sporadically with unknown aetiology, some 10% are inherited in an autosomal-dominant manner (Pasinelli and Brown, 2006).”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Clinical studies utilizing the administration of GLP-1 or Ex-4 have found that patients experience a decrease in caloric/food intake, hunger and body weight (Drucker and Nauck, 2006; Lovshin and Drucker, 2009; Vilsbøll et al., 2012).”
BackgroundBrain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Potential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
Hamster preproglucagon contains the sequence of glucagon and two related peptides
Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649 · cited 1×
“The peptide was first identified in the early 1980s (Bell et al., 1983).”
BackgroundIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease
Mattson, M. P. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1418.005 · Cited by 640
Depression in Parkinson disease—epidemiology, mechanisms and management
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.189 · Cited by 593
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 13×
“GLP-1 and Ex-4 dose-dependently protected SH-SY5Y cells from H2O2 induced cell death (Li et al., 2009; 2010b).”
BackgroundInfluentialSelf-citationTraumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?
Johnson, V. E., Stewart, W., & Smith, D. H. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2808 · Cited by 587 · cited 1×
“This is of relevance to neurodegenerative disorders as traumatic brain injury is considered a conduit to their later development (Johnson et al., 2010; Costanza et al., 2011).”
BackgroundHalagappa, V. K. M., Guo, Z., Pearson, M., Matsuoka, Y., Cutler, R. G., LaFerla, F. M., & Mattson, M. P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.12.019 · Cited by 580
Hasselmo, M. E. (2005) · Hippocampus · doi:10.1002/hipo.20116 · Cited by 502 · cited 5×
“…et al., 1999a), which are indicative of sedentary states of mental arousal associated with learning and memory retrieval and are believed to be vital to the induction of LTP 1590 British Journal of Pharmacology (2012) 166 1586–1599 (Hyman et al., 2003; Hasselmo, 2005; Kesner and Hopkins, 2006).”
BackgroundInfluentialCraft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487 · cited 1×
“Recently, a striking resemblance has been described between the altered metabolic status of the AD brain, with that of type 2 diabetes mellitus (T2DM) (Arvanitakis et al., 2004; Craft, 2007; Akter et al., 2011).”
BackgroundPrzedborski, S., Kostic, V, Jackson-Lewis, V, Naini, A., Simonetti, S., Fahn, S., Carlson, E., Epstein, C., & Cadet, J. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-05-01658.1992 · Cited by 456
Vilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 2×
“GLP-1 is rapidly digested by dipedylpeptidase-IV (DPP-IV) (Figure 1); a few minutes after its release into the blood stream, the majority of the incretin protein will have been degraded by this protease (Vilsbøll et al., 2003).”
BackgroundProbing the biology of Alzheimer’s disease in mice
Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413
Hyman, J. M., Wyble, B. P., Goyal, V., Rossi, C. A., & Hasselmo, M. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-37-11725.2003 · Cited by 404
Insulin resistance and Alzheimer's disease
De La Monte, S. M. (2009) · BMB Reports · doi:10.5483/bmbrep.2009.42.8.475 · Cited by 392 · cited 1×
“The stark similarity between T2DM and AD has given rise to the hypothesis and new term for describing AD as, namely, ‘type 3 diabetes’ (Steen et al., 2005; de la Monte, 2009; Kroner, 2009; Akter et al., 2011).”
BackgroundProtection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“Moreover, neurons challenged with glutamate, an NMDA receptor agonist, exhibited cell death marked by apoptosis, which was decreased with Ex-4 treatment (Perry et al., 2002b).”
BackgroundSelf-citationCampos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
Self-citationBertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Identification and Actions of Gastric Inhibitory Polypeptide
BROWN, J. C., DRYBURGH, J. R., ROSS, S. A., & DUPRÉ, J. (1975) · Proceedings of the 1974 Laurentian Hormone Conference · doi:10.1016/b978-0-12-571131-9.50017-7 · Cited by 333
The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?
Kroner, Z. (2009) · PubMed · Cited by 329
Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1314 · Cited by 321
Self-citationAlvarez, E., Martínez, M. D., Roncero, I., Chowen, J. A., García‐Cuartero, B., Gispert, J. D., Sanz, C., Vázquez, P., Maldonado, A., De Cáceres, J., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02914.x · Cited by 305
Perry, T., Lahiri, D. K., Chen, D., Zhou, J., Shaw, K. T. Y., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.958 · Cited by 300
Self-citationYamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294
Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 289
Abbas, T., Faivre, E., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · cited 1×
“The MPTP toxicity was fully reversed by Ex-4, which increased numbers of viable dopaminergic neurons and tempered the level of inflammation (Kim et al., 2009; Li et al., 2009).”
BackgroundIV. MPTP, MPP+ and mitochondrial function
Nicklas, W. J., Youngster, S. K., Kindt, M. V., & Heikkila, R. E. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90299-2 · Cited by 257
Rapid ATP Loss Caused by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine in Mouse Brain
Chan, P., DeLanney, L. E., Irwin, I., Langston, J. W., & Di Monte, D. (1991) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1991.tb02134.x · Cited by 241
Hayes, M. R., Leichner, T. M., Zhao, S., Lee, G. S., Chowansky, A., Zimmer, D., De Jonghe, B. C., Kanoski, S. E., Grill, H. J., & Bence, K. K. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.02.001 · Cited by 234
Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227 · cited 2×
“Conversely and not surprisingly, the GLP-1 receptor antagonist exendin(9– 36) reduced progenitor cell proliferation in these mice British Journal of Pharmacology (2012) 166 1586–1599 1589 (Hamilton et al., 2011), confirming that this action is GLP-1R mediated.”
BackgroundCyclic AMP Elevation Is Sufficient to Promote the Survival of Spinal Motor Neurons In Vitro
Hanson, M. G., Shen, S., Wiemelt, A. P., McMorris, F. A., & Barres, B. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-18-07361.1998 · Cited by 216
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
A mouse model of blast-induced mild traumatic brain injury
Rubovitch, V., Ten-Bosch, M., Zohar, O., Harrison, C. R., Tempel-Brami, C., Stein, E., Hoffer, B. J., Balaban, C. D., Schreiber, S., Chiu, W.-T., et al. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.09.018 · Cited by 209
Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207 · cited 1×
“GLP-1R stimulation has been shown to attenuate the synthesis of a pro-inflammatory cytokine (IL-1b) in activated astrocytes (Iwai et al., 2006).”
BackgroundTeramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201
Expression of the Glucagon‐Like Peptide‐1 Receptor Gene in Rat Brain
Alvarez, E., Roncero, I., Chowen, J. A., Thorens, B., & Blázquez, E. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66030920.x · Cited by 194
Animal models of Parkinson's disease
Jackson-Lewis, V., Blesa, J., & Przedborski, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70057-8 · Cited by 191
Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease
Sambamurti, K., Greig, N. H., & Lahiri, D. K. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:1:1:1 · Cited by 185
Self-citationAnimal models of the non-motor features of Parkinson's disease
McDowell, K. A., & Chesselet, M. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.040 · Cited by 182
Perry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K., Mattison, J. A., & Greig, N. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 182
Self-citationMartin, B., Golden, E., Carlson, O. D., Pistell, P., Zhou, J., Kim, W., Frank, B. P., Thomas, S., Chadwick, W. A., Greig, N. H., et al. (2009) · Diabetes · doi:10.2337/db08-0799 · Cited by 181
Self-citationAmyotrophic lateral sclerosis models and human neuropathology: similarities and differences
Kato, S. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0308-4 · Cited by 168
GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid
Gault, V. A., & Hölscher, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.025 · Cited by 168
Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice
D’Amico, M., Filippo, C. D., Marfella, R., Abbatecola, A. M., Ferraraccio, F., Rossi, F., & Paolisso, G. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.12.004 · Cited by 164
Isacson, R., Nielsen, E. I., Dannaeus, K., Bertilsson, G., Patrone, C., Zachrisson, O., & Wikström, L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.008 · Cited by 161
Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
Baggio, L. L., & Drucker, D. J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.110104.115624 · Cited by 161
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., & Hölscher, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.014 · Cited by 160
Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W., & Greig, N. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06731.x · Cited by 154
Self-citationEvaluating and treating unintentional weight loss in the elderly.
Huffman, G. B. (2002) · PubMed · Cited by 153
Mnemonic functions of the hippocampus: A comparison between animals and humans
Kesner, R. P., & Hopkins, R. O. (2006) · Biological Psychology · doi:10.1016/j.biopsycho.2006.01.004 · Cited by 149
Marchetti, C., & Marie, H. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.035 · Cited by 148
Liu, J., Yin, F., Zheng, X., Jing, J., & Hu, Y. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.04.021 · Cited by 145
Liu, J., Yin, F., Guo, L., Deng, X., & Hu, Y. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2008.25 · Cited by 144
Brain-derived neurotrophic factor as a drug target for CNS disorders
Pezet, S., & Malcangio, M. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.391 · Cited by 141
Belsham, D. D., Fick, L. J., Dalvi, P. S., Centeno, M.-L., Chalmers, J. A., Lee, P. K. P., Wang, Y., Drucker, D. J., & Koletar, M. M. (2009) · The FASEB Journal · doi:10.1096/fj.09-133454 · Cited by 138
Li, Y., Chigurupati, S., Holloway, H. W., Mughal, M. R., Tweedie, D., Bruestle, D. A., Mattson, M. P., Wang, Y., Harvey, B. K., Ray, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032008 · Cited by 135
Self-citationHypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus
Ross, S. A., Brown, J. C., & Dupré, J. (1977) · Diabetes · doi:10.2337/diab.26.6.525 · Cited by 135
Kimura, R., Okouchi, M., Fujioka, H., Ichiyanagi, A., Ryuge, F., Mizuno, T., Imaeda, K., Okayama, N., Kamiya, Y., Asai, K., et al. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.05.025 · Cited by 133
Perry, T., & Greig, N. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367892 · Cited by 127
Self-citationGilman, C. P., Perry, T., Furukawa, K., Grieg, N. H., Egan, J. M., & Mattson, M. P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02073.x · Cited by 125
The glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122
Self-citationLee, C. H., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 121
Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice
Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 120
Costanza, A., Weber, K., Gandy, S., Bouras, C., Hof, P. R., Giannakopoulos, P., & Canuto, A. (2011) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2011.01186.x · Cited by 116
Denton, T. A., & Howard, B. D. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb02909.x · Cited by 107
Greig, N. H., Mattson, M. P., Perry, T., Chan, S. L., Giordano, T., Sambamurti, K., Rogers, J. T., Ovadia, H., & Lahiri, D. K. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.018 · Cited by 106
Self-citationWhat is the Functional Relevance of Prefrontal Cortex Entrainment to Hippocampal Theta Rhythms?
Hyman, J. M., Hasselmo, M. E., & Seamans, J. K. (2011) · Frontiers in Neuroscience · doi:10.3389/fnins.2011.00024 · Cited by 104
The impact of dietary energy intake on cognitive aging
Mattson, M. P. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.005.2010 · Cited by 103
Heile, A., Wallrapp, C., Klinge, P. M., Samii, A., Kassem, M. S., Silverberg, G. D., & Brinker, T. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.07.071 · Cited by 103
Wang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99 · cited 2×
“However, pretreatment with Val(8)-GLP-1 improved performance in both parameters (Wang et al., 2010).”
BackgroundResultLi, L., Zhang, Z., Hölscher, C., Gao, C., Jiang, Y., & Liu, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.11.005 · Cited by 98
Feeding and hydration issues for older adults with dementia
Amella, E. J. (2004) · Nursing Clinics of North America · doi:10.1016/j.cnur.2004.02.014 · Cited by 93
Perry, T., & Greig, N. H. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4605 · Cited by 92
Self-citationIntravitreal Injection of Exendin-4 Analogue Protects Retinal Cells in Early Diabetic Rats
Zhang, Y., Zhang, J., Wang, Q., Lei, X., Chu, Q., Xu, G.-T., & Ye, W. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4727 · Cited by 92
Flament, S., Delacourte, A., & Mann, D. M. A. (1990) · Brain Research · doi:10.1016/0006-8993(90)90891-e · Cited by 89
GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
Jolivalt, C. G., Fineman, M., Deacon, C. F., Carr, R. D., & Calcutt, N. A. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01431.x · Cited by 87 · cited 2×
“…to attenuate streptozotocin-induced reductions of motor nerve conduction velocity and paw intraepidermal fibre density evident in diabetic mice (Jolivalt et al., 2011), as well as to significantly ameliorate diabetic polyneuropathy likewise in streptozotocin-induced diabetic mice (Himeno et…”
BackgroundEnergy metabolism in disorders of the nervous system.
Blass, J. P., Sheu, R., & Cedarbaum, J. M. (1988) · PubMed · Cited by 78
Qin, Z., Sun, Z., Huang, J., Hu, Y., Wu, Z., & Mei, B. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.08.047 · Cited by 71
Chowen, J. A., de Fonseca, F. R., Álvarez, E., Navarro, M. A., García‐Segura, L. M., & Blázquez, E. (1999) · Neuropeptides · doi:10.1054/npep.1999.0757 · Cited by 70
Glucocorticoid regulation of preproglucagon transcription and RNA stability during stress
Zhang, R., Packard, B. A., Tauchi, M., D’Alessio, D. A., & Herman, J. P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808716106 · Cited by 66
Protection of exendin-4 analogue in early experimental diabetic retinopathy
Zhang, Y., Wang, Q., Zhang, J., Lei, X., Xu, G.-T., & Ye, W. (2008) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-1004-3 · Cited by 63
Bradley, D. P., Kulstad, R., & Schoeller, D. A. (2010) · Nutrition · doi:10.1016/j.nut.2009.07.008 · Cited by 62
A Partial Failure of Membrane Protein Turnover May Cause Alzheimers Disease: A New Hypothesis
Sambamurti, K., Suram, A., Venugopal, C., Prakasam, A., Zhou, Y., Lahiri, D. K., & Greig, N. H. (2006) · Current Alzheimer Research · doi:10.2174/156720506775697142 · Cited by 62
Self-citationPyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy
Perry, T., Weerasuriya, A., Mouton, P. R., Holloway, H. W., & Greig, N. H. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.013 · Cited by 60
Self-citationGlucagon-like peptide-1 modulates neuronal activity in the ratʼs hippocampus
Oka, J., Goto, N., & Kameyama, T. (1999) · Neuroreport · doi:10.1097/00001756-199906030-00004 · Cited by 56
Biswas, S. C., Buteau, J., & Greene, L. A. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9646-4 · Cited by 55
Emerging drugs for amyotrophic lateral sclerosis
Habib, A. A., & Mitsumoto, H. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.604312 · Cited by 54
Subtype selective kainic acid receptor agonists: Discovery and approaches to rational design
Bunch, L., & Krogsgaard‐Larsen, P. (2008) · Medicinal Research Reviews · doi:10.1002/med.20133 · Cited by 52
Luciani, P., Deledda, C., Benvenuti, S., Cellai, I., Squecco, R., Monici, M., Cialdai, F., Luciani, G., Danza, G., Stefano, C. D., et al. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0398-3 · Cited by 50
Oka, J., Suzuki, E., & Kondo, Y. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02741-4 · Cited by 46
Calvo, J. C., Yusta, B., Mora, F., & Blázquez, E. (1995) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1995.64010299.x · Cited by 42
Yamagishi, S., & Matsui, T. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798999456 · Cited by 40
Li, H., Lee, C. H., Yoo, K.-Y., Choi, J. H., Park, O. K., Yan, B. C., Byun, K., Lee, B., Hwang, I. K., & Won, M.-H. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.040 · Cited by 39
Zhang, R., Zhang, H., Xu, L., Ma, K., Wallrapp, C., & Jonas, J. B. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2010.02044.x · Cited by 32
Calvo, J. C., GISOLFI, C. V., Blázquez, E., & Mora, F. (1995) · Brain Research Bulletin · doi:10.1016/0361-9230(95)02010-o · Cited by 28
Endogenous GLP-1 modulates hippocampal activity in β-amyloid protein-treated rats
Oka, J., Suzuki, E., Goto, N., & Kameyama, T. (1999) · Neuroreport · doi:10.1097/00001756-199909290-00016 · Cited by 26
Kang, D., Miyako, K., Kuribayashi, F., Hasegawa, E., Mitsumoto, A., Nagano, T., & Takeshige, K. (1997) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.9727 · Cited by 25
Lim, J., Lee, J.-J., Park, S.-H., Park, J.-H., Kim, S., Cho, H., Baek, W., Kim, D.-K., & Song, D. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.05.017 · Cited by 24
Best, J. H., Lavillotti, K., DeYoung, M. B., & Garrison, L. P. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01533.x · Cited by 21
Kovacic, P., Edwards, W. D., & Ming, G. (1991) · Free Radical Research Communications · doi:10.3109/10715769109088938 · Cited by 19
Research works printed but not linked: 2
- 10.1210/endo.134.5.8156917 · doi:10.1210/endo.134.5.8156917 · Paper page
- 10.1002/1097-4547(20001215)62:6<814::AID-JNR8>3.0.CO;2-F · doi:10.1002/1097-4547(20001215)62:6<814::aid-jnr8>3.0.co;2-f
Cited by
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
Yun, S. P., Kam, T.-I., Panicker, N., Kim, S., Oh, Y., Park, J.-S., Kwon, S.-H., Park, Y. J., Karuppagounder, S. S., Park, H., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0051-5 · Cited by 1,123
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“In addition, they have been shown to enhance synaptic transmission and counteract learning deficits (30, 31).”
BackgroundInfluentialBrain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Athauda, D., & Foltynie, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.01.013 · Cited by 383
“R e ie w s K E Y N O T E R E V IE W 139 Salcedo, I. et al. (2012) Neuroprotective and neurotrophic actions of glucagon-like”
BackgroundThe Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 304
Metadata
- Authors
- Salcedo, I., Tweedie, D., Li, Y., & Greig, N. H.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-06-21
- Volume
- 166
- Issue
- 5
- Pages
- 1586-1599
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1546941007
- Cited by
- 259
- References
- 123
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.